Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM-CT-01 + Peptide Vaccine in Advanced Metastatic Melanoma
NCT01723813Phase 2Terminated
- Start
- Apr 2012
- Primary completion
- Apr 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of exidavnemab in melanoma. Started Apr 2012; status: terminated.
02
Drugs
exidavnemab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01723813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01723813.